A UNC5-fusion protein comprising the two lg-like domains of UNC5A, UNC5B, UNC5C or UNC5D and an antibody Fc-part. A pharmaceutical composition comprising such a fusion protein or a nucleic acid, vector or host cell able to produce the fusion protein. The pharmaceutical composition is useful in the treatment of cancer and especially a cancer with netrin-1 over expression.